New health care proxies for Parkinson's disease dementia, dementia that develops in Parkinson's, must address psychosis, falls, swallowing, driving, and drugs. The National Institute on Aging describes a proxy as the person who decides care when the patient cannot communicate, covering safety and drug choices.
The Parkinson's Foundation reports about 30% of people with Parkinson's never develop dementia Parkinson's Foundation briefing on predicting dementia. The foundation adds that risk rises with mild cognitive impairment, older age, longer duration, and worse motor symptoms. The National Institute on Aging urges proxies, also called representatives, surrogates, or agents, to share papers and contact details with the care team.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What do hallucinations and delusions look like?
- Which changes need prompt medical review?
- How do I reduce falls and choking risk?
- Is driving still safe?
- What drug questions should I ask the doctor?
What do hallucinations and delusions look like?
The Michael J. Fox Foundation describes Parkinson's psychosis as visual hallucinations, such as seeing people who are not there. It also includes delusions, such as false beliefs about infidelity or theft.
For a proxy, the detail matters: note what was seen or believed, when it happened, and how the person acted. The same foundation says psychosis usually appears years into Parkinson's disease. It sometimes accompanies dementia. That timing helps proxies avoid mistaking an early isolated symptom for long-term psychosis.
Which changes need prompt medical review?
The Michael J. Fox Foundation lists several triggers that can start or worsen psychosis episodes. Proxies should seek prompt medical review when a new trigger appears or symptoms worsen.
Bring a full drug list, including over-the-counter sleep or allergy pills. Note recent fever, cough, burning with urination, surgery, travel, or poor sleep. A short written timeline helps the clinician sort drug effects from infection.
- Parkinson's drugs such as dopamine agonists and amantadine
- Benadryl
- infections like urinary tract infections or pneumonia
- unfamiliar settings, surgery, and sleep disruption
How do I reduce falls and choking risk?
Parkinson's disease can impair balance and coordination and sometimes causes falls, according to the National Institute on Aging National Institute on Aging page on Parkinson's causes, symptoms, and treatments. Proxies should check supervision needs after any fall or near fall. Look for rugs, cords, poor light, and missing rails or aids.
The same agency notes difficulty swallowing, chewing, and speaking. Those problems create choking and aspiration-pneumonia risks. Proxies should confirm a feeding and supervision plan with the care team.
Is driving still safe?
Families watching for unsafe driving should seek a comprehensive driving evaluation, according to the Alzheimer's Association Alzheimer's Association guidance on dementia and driving. The evaluation is done by an occupational therapy driving rehabilitation specialist. It objectively measures how dementia affects driving and produces a safety plan.
Do not rely on family observation alone. Bring notes on dents, near misses, getting lost, or slow reactions. Ask what limits or stopping driving the plan recommends and what rides can fill the gap.
What drug questions should I ask the doctor?
Pimavanserin (Nuplazid) is FDA-approved for hallucinations and delusions of Parkinson's disease psychosis, according to U.S. Food and Drug Administration prescribing information FDA prescribing information for pimavanserin. Its label carries a boxed warning of increased death in elderly patients with dementia-related psychosis.
The label bars use for psychosis unrelated to Parkinson's disease. Rivastigmine (Exelon) is FDA-indicated for mild-to-moderate dementia linked to Parkinson's disease, as reviewed by Parkinson's News Today against its July 2007 FDA approval. As a cholinesterase inhibitor, it raises acetylcholine levels. It does not change the underlying disease process.
